Department of Surgery, Universitas Padjadjaran/Hasan Sadikin General Hospital, West Java, Bandung, Indonesia.
Division of Digestive Surgery, Department of Surgery, Universitas Padjadjaran/Hasan Sadikin General Hospital, West Java, Bandung, Indonesia.
J Gastrointest Cancer. 2024 Nov 18;56(1):22. doi: 10.1007/s12029-024-01142-3.
Colorectal cancer is the third most common cancer with the second highest mortality worldwide in 2020. Adjuvant chemotherapy is given for stage II-III colorectal cancer. However, there are side effects that decrease the patient's quality of life. Several studies have found that vitamin D could reduce the side effects of chemotherapy, but studies at Hasan Sadikin Hospital have not been done.
A study regarding the effect of vitamin D supplementation on the quality of life of stage II-III colorectal cancer patients undergoing adjuvant chemotherapy from May 2022 to April 2023 at Hasan Sadikin Hospital was conducted. A single-blinded, randomized controlled trial (RCT) with consecutive sampling was done at the digestive surgery outpatients. Data was taken from the medical record, history taking, and personal interviews. Quality of life was measured at the first, third, and sixth months after chemotherapy using the validated Indonesian version of the EORTC QLQ-C30 questionnaire.
A total of 34 patients received vitamin D and 34 others received placebo. Serum vitamin D levels significantly increased (p < 0.001) in the intervention arm, from a median of 21.34 (5.26-29.95) to 27.92 (13.58-40.49). Meanwhile, it decreased in the placebo arm, from a median of 22.78 (8.3-29.93) to 21.37 (7.45-31.26). The patient's quality of life improved significantly after receiving vitamin D, compared with the placebo group on the third (median of 75.0 vs 45.83) and sixth (median of 83.33 vs 33.33) months after chemotherapy.
Vitamin D consumption (10,000 IU/day) could improve the quality of life of colorectal cancer patients undergoing adjuvant chemotherapy.
2020 年,结直肠癌是全球发病率第三、死亡率第二高的癌症。Ⅱ-Ⅲ期结直肠癌患者需要接受辅助化疗。但是,化疗有副作用,会降低患者的生活质量。有几项研究发现维生素 D 可以降低化疗的副作用,但 Hasan Sadikin 医院尚未开展相关研究。
本研究于 2022 年 5 月至 2023 年 4 月在 Hasan Sadikin 医院开展,采用单盲、随机对照试验(RCT),连续抽样,在消化外科门诊进行。从病历、病史询问和个人访谈中获取数据。在化疗后第 1、3、6 个月使用经过验证的印尼版 EORTC QLQ-C30 问卷评估生活质量。
共纳入 34 例接受维生素 D 治疗的患者和 34 例接受安慰剂治疗的患者。干预组血清维生素 D 水平显著升高(p<0.001),中位数从 21.34(5.26-29.95)升至 27.92(13.58-40.49)。而安慰剂组则下降,中位数从 22.78(8.30-29.93)降至 21.37(7.45-31.26)。与安慰剂组相比,接受维生素 D 的患者在化疗后第 3 个月(中位数 75.0 vs 45.83)和第 6 个月(中位数 83.33 vs 33.33)时生活质量显著改善。
维生素 D(10,000 IU/天)的摄入可以改善接受辅助化疗的结直肠癌患者的生活质量。